av Canada has high regulatory standards for the approval of new therapeutic products. Before a product is made available for use by Canadians, it must be proven safe and effective through rigorous pre- and clinical trials. This process minimizes the harm to the public. Currently, the Canadian Government is reforming the regulations in order to expedite the approval of novel drugs to the market, exposing healthy Canadians to potentially high risk products. In a two part interview, Deanna McLeod takes a closer look at these changes, the proposed amendments, and their potential impact for Canadians’ rights to informed consent and personalized health care.
